Study guide
1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics
Philippine Medical Technologists Licensure Examination MTLE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety
1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards
2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function
2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice
3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology
3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology
4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety
4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms
5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria
5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology
6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology
6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods
7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods
7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control
8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders
8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry
9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders
9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests
10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing
10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures
11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions
11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin
12 Chapter 12: Clinical Serology and Immunology
12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)
13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology
13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control
14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens
14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens
15 Chapter 15: Histopathologic Techniques and Cytotechnology
15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records
16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics
16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics
1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics
Key Takeaways Explain This Topic AI
Gaussian distribution parameters form the basis of statistical quality control: 68.3 % 68.3\% 68.3% of values lie within ± 1 s \pm 1s ± 1 s , 95.5 % 95.5\% 95.5% within ± 2 s \pm 2s ± 2 s , and 99.7 % 99.7\% 99.7% within ± 3 s \pm 3s ± 3 s around the target mean.
Random error represents analytical imprecision (e.g., pipetting bubbles, electrical line noise), whereas systematic error represents directional bias and inaccuracy (e.g., calibration shift, reagent degradation, declining photometer lamp).
Westgard multirules minimize false rejection ( P f r P_{fr} P f r ) while maximizing error detection ( P e d P_{ed} P e d ): 1 3 s 1_{3s} 1 3 s and R 4 s R_{4s} R 4 s detect acute random errors, while 2 2 s 2_{2s} 2 2 s , 4 1 s 4_{1s} 4 1 s , and 10 x 10_x 1 0 x signal systematic errors.
Failed quality control must never be bypassed by re-running controls repeatedly or averaging; a disciplined troubleshooting cascade (physical inspection → \to → fresh aliquot → \to → new reagent → \to → recalibration) is mandated.
Clinical laboratory calculations require absolute mastery of dilution equations ( C 1 V 1 = C 2 V 2 C_1 V_1 = C_2 V_2 C 1 V 1 = C 2 V 2 ), serial dilutions, molarity, normality, and the anion gap formula ( [ Na + ] − ( [ Cl − ] + [ HCO 3 − ] ) [\text{Na}^+] - ([\text{Cl}^-] + [\text{HCO}_3^-]) [ Na + ] − ([ Cl − ] + [ HCO 3 − ]) ).
Last updated: October 2026
Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics
Statistical Quality Control (QC) in clinical chemistry monitors analytical precision, detects method bias, and prevents erroneous patient data release. For the medical laboratory scientist, quality control is an active troubleshooting discipline rooted in metrology and mathematics.
1. Statistical Quality Control Parameters and Gaussian Distribution
Statistical QC assumes analytical measurements on stable control materials follow a Gaussian (normal) distribution —a symmetrical, bell-shaped probability density curve characterized by the mean ( x ˉ \bar{x} x ˉ ) and standard deviation ( s s s ). Gaussian Distribution
- │
- ┌─┴─┐
- ┌─┘ └─┐
- ┌─┘ └─┐
- ┌─┘ └─┐
- ┌─┘ └─┐
- ───┴───────────────────┴───
- 3s -2s -1s x̄ +1s +2s +3s
- ├────── 68.27% ─────┤
- ├────────── 95.45% ─────────┤
- ├────────────── 99.73% ─────────────┤
- Statistical Parameters
Mean ( x ˉ \bar{x} x ˉ ) : The arithmetic average of all data points; represents analytical accuracy (trueness) : x ˉ = ∑ x i n \bar{x} = \frac{\sum x_i}{n} x ˉ = n ∑ x i
Standard Deviation ( s s s or SD) : Quantifies data dispersion around the mean; represents analytical precision (or imprecision) : s = ∑ ( x i − x ˉ ) 2 n − 1 s = \sqrt{\frac{\sum (x_i - \bar{x})^2}{n - 1}} s = n − 1 ∑ ( x i − x ˉ ) 2
Variance ( s 2 s^2 s 2 ) : The square of standard deviation, used in statistical comparisons (such as the F F F -test for method comparison).
Coefficient of Variation ( C V % CV\% C V % ) : The standard deviation expressed as a percentage of the mean: C V % = ( s x ˉ ) × 100 % CV\% = \left(\frac{s}{\bar{x}}\right) \times 100\% C V % = ( x ˉ s ) × 100% Because C V % CV\% C V % is dimensionless, it enables direct comparison of analytical precision between different instruments, methodologies, or concentration levels (e.g., assessing if low-level troponin is as precise as high-level troponin).
Gaussian Confidence Intervals
x ˉ ± 1 s \bar{x} \pm 1s x ˉ ± 1 s : Encloses 68.27 % 68.27\% 68.27% of all observations.
x ˉ ± 2 s \bar{x} \pm 2s x ˉ ± 2 s : Encloses 95.45 % 95.45\% 95.45% of all observations. In single-rule 1 2 s 1_{2s} 1 2 s systems, approximately 4.55 % 4.55\% 4.55% (1 in 22) of valid in-control runs fall outside ± 2 s \pm 2s ± 2 s purely by random chance.
x ˉ ± 3 s \bar{x} \pm 3s x ˉ ± 3 s : Encloses 99.73 % 99.73\% 99.73% of all observations. Only 0.27 % 0.27\% 0.27% (1 in 370 observations) will fall outside ± 3 s \pm 3s ± 3 s when the method is stable. Points beyond ± 3 s \pm 3s ± 3 s indicate true analytical error.
2. Levey-Jennings Control Charts and Error Classification
A Levey-Jennings (L-J) chart plots daily control measurements across time (x-axis) against established statistical limits (y-axis: x ˉ , ± 1 s , ± 2 s , ± 3 s \bar{x}, \pm 1s, \pm 2s, \pm 3s x ˉ , ± 1 s , ± 2 s , ± 3 s ). Analytical errors manifest as characteristic patterns: +3s ──────────────────────────────────────────────────────── (Action Limit)
- +2s ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ (Warning Limit)
- +1s ························································
- x̄ ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ (Target Mean)
- 1s ························································
- 2s ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ ─ (Warning Limit)
- 3s ──────────────────────────────────────────────────────── (Action Limit)
- Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
- Random Error (Imprecision)
Nature : Unpredictable, non-directional deviations in either direction from the mean. Affects the reproducibility and spread ( s , C V % s, CV\% s , C V % ) of the assay.
Underlying Causes : Air bubbles in reagent or sample lines, transient voltage spikes in electrical power lines, particulate contamination in cuvettes, pipetting tip leakage, or photometer lamp flicker.
L-J Appearance : Increased scatter of individual points across both sides of the mean; violations of 1 3 s 1_{3s} 1 3 s or R 4 s R_{4s} R 4 s rules.
Systematic Error (Inaccuracy / Bias)
Nature : Predictable, unidirectional drift or step-shift in values away from the target mean. Shifts the observed mean while standard deviation may remain narrow.
Patterns on Levey-Jennings :
Trend : A gradual, continuous progression of control values in one direction away from the mean across ≥ 6 \ge 6 ≥ 6 consecutive runs . Caused by: slow deterioration of reconstituted reagents, aging of the photometer excitation lamp, gradual buildup of protein bio-film in flow cells, or slow evaporation of control material in open sample carousels.
Shift : An abrupt, sustained change in control values that maintains a new mean above or below the target across ≥ 6 \ge 6 ≥ 6 consecutive runs . Caused by: introduction of a new reagent lot with an inaccurate calibrator assignment factor, sudden change in incubator chamber temperature, incorrect recalibration, or syringe pipettor slippage.
3. The Westgard Multirule Decision Algorithm
Formulated by Dr. James O. Westgard, the multirule algorithm combines statistical decision criteria to maximize the Probability of Error Detection ( P e d P_{ed} P e d ) while keeping the Probability of False Rejection ( P f r P_{fr} P f r ) below 1 % 1\% 1% . ┌───────────────────────────────┐
- │ Perform Daily Control Run │
- │ (e.g., Level 1, Level 2) │
- └───────────────┬───────────────┘
- │
- ▼
- ┌───────────────────────────────┐
- │ Does ANY control exceed 2s? │
- │ (Rule 1₂ₛ) │
- └───────┬───────────────┬───────┘
- │ NO │ YES (Warning trigger)
- ▼ ▼
┌────────────────┐ Inspect Multirules:
- │ ACCEPT RUN │ ├─ 1₃ₛ (Any value > 3s?) ──► REJECT (Random Error)
- │ Report Results │ ├─ 2₂ₛ (2 in a row > 2s?) ──► REJECT (Systematic Error)
- └────────────────┘ ├─ R₄ₛ (Span > 4s in run?) ─► REJECT (Random Error)
- ├─ 4₁ₛ (4 in a row > 1s?) ──► REJECT (Systematic Error)
- └─ 10ₓ (10 on same side?) ──► REJECT (Systematic Error)
Westgard Rule Classification Definition / Criteria Type of Error Detected Required Action
1 2 s 1_{2s} 1 2 s Warning Only One control value exceeds x ˉ ± 2 s \bar{x} \pm 2s x ˉ ± 2 s Screening trigger Do NOT reject run . Screen data against remaining rules.
1 3 s 1_{3s} 1 3 s Rejection One control value exceeds x ˉ ± 3 s \bar{x} \pm 3s x ˉ ± 3 s Random Error (or large systematic) Reject the analytical run . Withhold patient results.
2 2 s 2_{2s} 2 2 s Rejection Two consecutive controls exceed the same limit ( + 2 s +2s + 2 s or − 2 s -2s − 2 s ) Systematic Error Reject the analytical run . Withhold patient results.
R 4 s R_{4s} R 4 s Rejection Within a single run, one control exceeds + 2 s +2s + 2 s and another exceeds − 2 s -2s − 2 s ( > 4 s >4s > 4 s span) Random Error Reject the analytical run . Withhold patient results.
4 1 s 4_{1s} 4 1 s Rejection Four consecutive controls exceed the same + 1 s +1s + 1 s or − 1 s -1s − 1 s limit Systematic Error Reject the analytical run . Withhold patient results.
10 x 10_x 1 0 x Rejection Ten consecutive control measurements fall on one side of the mean Systematic Error Reject the analytical run . Withhold patient results.
Application Scope : Rules such as 2 2 s 2_{2s} 2 2 s , 4 1 s 4_{1s} 4 1 s , and 10 x 10_x 1 0 x can be applied within-run across control levels (e.g., Level 1 at + 2.2 s +2.2s + 2.2 s and Level 2 at + 2.4 s +2.4s + 2.4 s violates 2 2 s 2_{2s} 2 2 s ) or across consecutive runs for a single control level .
4. Systematic Troubleshooting Protocol for QC Failures
When a Westgard rejection rule triggers, laboratory technologists must adhere to a structured corrective action cascade:
Do NOT blindly repeat the control : Re-running the identical vial hoping it falls within ± 2 s \pm 2s ± 2 s creates false acceptance of an unstable analytical run. A single control repeated 20 times will statistically fall inside 2 s 2s 2 s purely by chance.
Do NOT average control results : Averaging disguises true random and systematic errors.
Step 1: Physical Inspection : Check reagent levels, fluidic tubing for air bubbles, sample probe alignment, wash block aspiration, and incubator bath temperature readouts.
Step 2: Re-run the Same Aliquot : Rules out an isolated physical artifact (e.g., tiny meniscus air bubble or temporary voltage dip).
Step 3: Test a Fresh Aliquot : Reconstitute or thaw a new, unopened vial of control material. If the fresh aliquot recovers on target, the problem was control degradation, evaporation, or vial contamination.
Step 4: Inspect Reagents : Check reagent open-vial expiration dates, lot changes, and physical appearance (turbidity, discoloration, precipitation). Load a fresh reagent cartridge.
Step 5: Perform Recalibration : Recalibrate the assay using fresh calibrator materials. Inspect the calibration curve parameters (slope, y-intercept, and R 2 R^2 R 2 fit).
Step 6: Hardware Maintenance : If fresh reagent and recalibration fail, replace photometer lamps, clean sample probe fluidics, replace peristaltic pump tubing, or contact manufacturer technical support.
Critical Patient Protection : After resolving the root cause and verifying QC acceptability, re-run all patient samples analyzed since the last documented acceptable QC run .
5. Calibration Hierarchy, Standards, and Metrological Traceability
Calibrator versus Quality Control Material :
Calibrator : A substance with an established analyte concentration assigned by primary reference methods. It establishes the instrument response curve (signal-to-concentration mathematical relationship). Calibrators must never be used as daily QC controls , as doing so creates circular validation that masks calibration errors.
Control : A matrix-matched material (e.g., human serum base) with target means and standard deviations, treated identically to patient specimens to verify ongoing method stability.
Traceability Hierarchy (ISO 17511) : Primary Reference Method (e.g., ID-MS) ⟶ Primary Calibrator (Pure Substance) \text{Primary Reference Method (e.g., ID-MS)} \longrightarrow \text{Primary Calibrator (Pure Substance)} Primary Reference Method (e.g., ID-MS) ⟶ Primary Calibrator (Pure Substance) ↓ \downarrow ↓ Secondary Reference Measurement ⟶ Secondary Matrix-Matched Calibrator (WHO, NIST) \text{Secondary Reference Measurement} \longrightarrow \text{Secondary Matrix-Matched Calibrator (WHO, NIST)} Secondary Reference Measurement ⟶ Secondary Matrix-Matched Calibrator (WHO, NIST) ↓ \downarrow ↓ Manufacturer Working Calibrator ⟶ Manufacturer Commercial Product Calibrator \text{Manufacturer Working Calibrator} \longrightarrow \text{Manufacturer Commercial Product Calibrator} Manufacturer Working Calibrator ⟶ Manufacturer Commercial Product Calibrator ↓ \downarrow ↓ Routine End-User Clinical Laboratory Analyzer ⟶ Reportable Patient Result \text{Routine End-User Clinical Laboratory Analyzer} \longrightarrow \text{Reportable Patient Result} Routine End-User Clinical Laboratory Analyzer ⟶ Reportable Patient Result
- 6. Clinical Chemistry Mathematics and Diagnostic Formulas
- Dilution Calculations
The General Dilution Equation : C 1 V 1 = C 2 V 2 C_1 V_1 = C_2 V_2 C 1 V 1 = C 2 V 2 Where C 1 C_1 C 1 and V 1 V_1 V 1 are the initial concentration and volume, and C 2 C_2 C 2 and V 2 V_2 V 2 are the final concentration and volume.
Dilution Factor (DF) : The ratio of total final volume to original sample volume: DF = V final V sample = V sample + V diluent V sample \text{DF} = \frac{V_{\text{final}}}{V_{\text{sample}}} = \frac{V_{\text{sample}} + V_{\text{diluent}}}{V_{\text{sample}}} DF = V sample V final = V sample V sample + V diluent To calculate patient concentration, multiply the instrument reading of the diluted sample by DF \text{DF} DF .
Serial Dilutions : In a series of consecutive dilutions, the overall dilution factor is the mathematical product of the individual dilution steps: Total DF = DF 1 × DF 2 × DF 3 × … \text{Total DF} = \text{DF}_1 \times \text{DF}_2 \times \text{DF}_3 \times \dots Total DF = DF 1 × DF 2 × DF 3 × …
Molarity and Normality
Molarity ( M M M ) : Moles of solute per liter of total solution: M = moles of solute Volume in Liters = mass (g) Molecular Weight (g/mol) × V (L) M = \frac{\text{moles of solute}}{\text{Volume in Liters}} = \frac{\text{mass (g)}}{\text{Molecular Weight (g/mol)} \times V \text{ (L)}} M = Volume in Liters moles of solute = Molecular Weight (g/mol) × V (L) mass (g)
Normality ( N N N ) : Chemical equivalents of solute per liter of solution: N = M × valence = mass (g) Equivalent Weight × V (L) where Equivalent Weight = MW valence N = M \times \text{valence} = \frac{\text{mass (g)}}{\text{Equivalent Weight} \times V \text{ (L)}} \quad \text{where } \text{Equivalent Weight} = \frac{\text{MW}}{\text{valence}} N = M × valence = Equivalent Weight × V (L) mass (g) where Equivalent Weight = valence MW For example: A 1.0 M 1.0\text{ M} 1.0 M solution of sulfuric acid ( H 2 SO 4 \text{H}_2\text{SO}_4 H 2 SO 4 , which has 2 2 2 ionizable protons) has a normality of 1.0 × 2 = 2.0 N 1.0 \times 2 = 2.0\text{ N} 1.0 × 2 = 2.0 N .
The Serum Anion Gap (AG)
The anion gap reflects the concentration of unmeasured anions (proteins, organic acids, phosphates, sulfates) relative to unmeasured cations ( C a 2 + , M g 2 + Ca^{2+}, Mg^{2+} C a 2 + , M g 2 + , gamma-globulins) in serum.
Formula 1 (Without Potassium—standard modern practice) : AG = [ Na + ] − ( [ Cl − ] + [ HCO 3 − ] ) Reference Interval: 8 to 16 mmol/L \text{AG} = [\text{Na}^+] - ([\text{Cl}^-] + [\text{HCO}_3^-]) \quad \text{Reference Interval: } 8\text{ to }16\text{ mmol/L} AG = [ Na + ] − ([ Cl − ] + [ HCO 3 − ]) Reference Interval: 8 to 16 mmol/L
Formula 2 (With Potassium) : AG = ( [ Na + ] + [ K + ] ) − ( [ Cl − ] + [ HCO 3 − ] ) Reference Interval: 10 to 20 mmol/L \text{AG} = ([\text{Na}^+] + [\text{K}^+]) - ([\text{Cl}^-] + [\text{HCO}_3^-]) \quad \text{Reference Interval: } 10\text{ to }20\text{ mmol/L} AG = ([ Na + ] + [ K + ]) − ([ Cl − ] + [ HCO 3 − ]) Reference Interval: 10 to 20 mmol/L
Clinical Interpretations of the Anion Gap
High Anion Gap Metabolic Acidosis (HAGMA) : Occurs when unmeasured fixed organic acids accumulate, consuming bicarbonate buffer. Key etiologies are summarized by the classic mnemonics MUDPILES and GOLD MARK :
- M ethanol (metabolized to formic acid)
- U remia (renal failure causing phosphate/sulfate retention)
- D iabetic Ketoacidosis (acetoacetic acid, β \beta β -hydroxybutyric acid)
- P ropylene glycol / Paraldehyde
- I soniazid / Iron intoxication
- L actic acidosis (hypoperfusion, tissue hypoxia, shock)
- E thylene glycol (metabolized to oxalic and glycolic acids)
- S alicylate overdose (salicylic acid accumulation + uncoupled oxidative phosphorylation)
Low Anion Gap ( < 6 mmol/L <6\text{ mmol/L} < 6 mmol/L ) :
Severe Hypoalbuminemia : Albumin is the primary unmeasured anion in normal serum, accounting for ≈ 75 % \approx 75\% ≈ 75% of the normal anion gap. For every 1.0 g/dL 1.0\text{ g/dL} 1.0 g/dL drop in serum albumin below 4.0 g/dL 4.0\text{ g/dL} 4.0 g/dL , the expected anion gap drops by approximately 2.5 mmol/L 2.5\text{ mmol/L} 2.5 mmol/L : Corrected AG = Observed AG + 2.5 × ( 4.0 − [ Albumin in g/dL ] ) \text{Corrected AG} = \text{Observed AG} + 2.5 \times (4.0 - [\text{Albumin in g/dL}]) Corrected AG = Observed AG + 2.5 × ( 4.0 − [ Albumin in g/dL ])
Multiple Myeloma : Accumulation of positively charged cationic paraproteins (IgG) increases unmeasured cations.
Bromide Intoxication : Bromide ions cross-react and bind avidly to chloride ISE membranes, producing spuriously elevated chloride readings that falsely collapse or yield negative anion gaps.